Related references
Note: Only part of the references are listed.Development of a high-throughput assay to identify inhibitors of the ubiquitin-conjugating enzyme UBCH10
Patrick Cleroux et al.
SLAS DISCOVERY (2022)
p21 produces a bioactive secretome that places stressed cells under immunosurveillance
Ines Sturmlechner et al.
SCIENCE (2021)
Ubiquitin signaling in cell cycle control and tumorigenesis
Fabin Dang et al.
CELL DEATH AND DIFFERENTIATION (2021)
UbcH10 a Major Actor in Cancerogenesis and a Potential Tool for Diagnosis and Therapy
Ivan Presta et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment
Marc L. Hyer et al.
NATURE MEDICINE (2018)
Deubiquitylation and stabilization of p21 by USP11 is critical for cell-cycle progression and DNA damage responses
Tanggang Deng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Ubiquitin ligases in oncogenic transformation and cancer therapy
Daniela Senft et al.
NATURE REVIEWS CANCER (2018)
Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential
Yangbo Feng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Julia A. Beaver et al.
CLINICAL CANCER RESEARCH (2015)
The history and future of targeting cyclin-dependent kinases in cancer therapy
Uzma Asghar et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
The ubiquitin proteasome system - Implications for cell cycle control and the targeted treatment of cancer
Florian Bassermann et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2014)
Design, synthesis and preliminary evaluation of a series of histone deacetylase inhibitors carrying a benzodiazepine ring
L. Guandalini et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2013)
Multiple degradation pathways regulate versatile CIP/KIP CDK inhibitors
Natalia G. Starostina et al.
TRENDS IN CELL BIOLOGY (2012)
Pharmacologic Inhibition of the Anaphase-Promoting Complex Induces A Spindle Checkpoint-Dependent Mitotic Arrest in the Absence of Spindle Damage
Xing Zeng et al.
CANCER CELL (2010)
Ubiquitylation and proteasomal degradation of the p21Cip1, p27Kip1 and p57Kip2 CDK inhibitors
Zhimin Lu et al.
CELL CYCLE (2010)
CRL2LRR-1 Targets a CDK Inhibitor for Cell Cycle Control in C. elegans and Actin-Based Motility Regulation in Human Cells
Natalia G. Starostina et al.
DEVELOPMENTAL CELL (2010)
The E2 Ubiquitin-conjugating Enzymes Direct Polyubiquitination to Preferred Lysines
Yael David et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Cell cycle kinases as therapeutic targets for cancer
Silvia Lapenna et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Identification of a physiological E2 module for the human anaphase-promoting complex
Adam Williamson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
p21 in cancer: intricate networks and multiple activities
Tarek Abbas et al.
NATURE REVIEWS CANCER (2009)
PCNA-dependent regulation of p21 ubiquitylation and degradation via the CRL4Cdt2 ubiquitin ligase complex
Tarek Abbas et al.
GENES & DEVELOPMENT (2008)
The CRL4Cdt2 ubiquitin ligase targets the degradation of p21Cip1 to control replication licensing
Youngjo Kim et al.
GENES & DEVELOPMENT (2008)
CDK Inhibitor p21 Is Degraded by a Proliferating Cell Nuclear Antigen-coupled Cul4-DDB1Cdt2 Pathway during S Phase and after UV Irradiation
Hideo Nishitani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
APC/CCdc20 controls the ubiquitin-mediated degradation of p21 in prometaphase
Virginia Amador et al.
MOLECULAR CELL (2007)
Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase
G Bornstein et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21
MA Shibata et al.
CANCER GENE THERAPY (2001)
Share Paper
